Caladrix is led by a global team with expertise in neurodegeneration, translational research, clinical drug development and company building. The executive team brings decades of experience in biotech, transporter biology and entrepreneurship across varied industries. The lead clinical investigators and board includes leaders in biomarker discovery, protein clearance mechanisms and FDA sanctioned neuroscience trial methodology.
Directors

Jonas Fischer
CO-FOUNDER & CEO

Dr. Markus Krohn
CO-FOUNDER & CSO

Max Brattig
CO-FOUNDER & CFO
Board
Prof. Peter Lansbury
CHAIRMAN
David Oxley
MEMBER OF THE BOARD
Michael Messemer
MEMBER OF THE BOARD
Edward Capel-Cure
MEMBER OF THE BOARD